secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2026-08-06T11:13:50+00:00
Accession:  0001635088-26-000088
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant Q1 net loss $290.6M; cash $3.9B; brepocitinib launch on track for Sept 2026
--------------------------------------------------------------------------------

- Net loss of $290.6M ($0.26 per share) vs $273.9M ($0.33) in prior-year quarter; revenue $1.4M.
- Cash, equivalents, and marketable securities of $3.9B as of June 30, 2026; repurchased 7.3M shares for $208.7M in Q1.
- Brepocitinib on track for DM launch by end of September 2026; Phase 3 CS (BEACON+) enrolled first patients; NIU data H2 2026.
- Genevant received $950M from Moderna in July under $2.25B settlement; additional $1.3B contingent on §1498 appeal; new lawsuits against Pfizer/BioNTech in 21 jurisdictions.
- R&D expenses rose to $202M (+$49.1M) and G&A to $165.5M (+$31.5M), partly due to Moderna settlement bonuses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/0001635088-26-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/roiv-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001635088-26-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer